Clinical Trial Update: Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus

View source ↗

Summary

A completed clinical trial assessing changes in cognitive function and cerebral blood flow after switching from calcineurin inhibitors to Everolimus in patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: End Stage Renal Disease | Status: COMPLETED